Rhythm gains on EU backing for rare obesity drug
IMCIVREE set for European approval after CHMP endorsement for hypothalamic obesity
Rhythm Pharmaceuticals shares rose 2.5% to $84.62 on Thursday after European regulators endorsed expanding the use of IMCIVREE, the company's flagship therapy for rare forms of obesity, marking a significant milestone in its push to establish a global presence.
The Boston-based biopharmaceutical company received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending approval of IMCIVREE (setmelanotide) for the treatment of obesity and control of hunger in adults and children aged four and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. A final decision from the European Commission is expected in the second quarter of 2026, according to company's press release.
Acquired hypothalamic obesity is a rare neuroendocrine disease characterized by accelerated and sustained weight gain resulting from damage to the hypothalamus, which disrupts the MC4R pathway that regulates appetite and energy expenditure. The condition frequently develops following the growth or treatment of craniopharyngioma, astrocytoma, or other hypothalamic-pituitary tumors, and can also be caused by traumatic brain injury, stroke, inflammation, or anatomical abnormalities.
"This positive CHMP opinion, combined with our recent FDA approval, validates the quality of the data which supports our filings in acquired HO and confirms our global drug development approach," said David Meeker, Rhythm's chairman, president and chief executive officer. "Acquired HO represents a significant unmet medical need across geographies and a unique opportunity for Rhythm."
The company estimates approximately 10,000 people in the United States and another 10,000 in the European Union are living with acquired hypothalamic obesity. Professor Hanneke van Santen, a pediatric endocrinology professor, emphasized the urgent need for new treatment options, noting that the disease "has a devastating impact" and that "existing approaches for managing weight are often ineffective" for these patients.
Rhythm, which focuses on developing therapies for rare genetic diseases of obesity, currently has a market capitalization of $5.78 billion. The stock's Thursday rally came on above-average volume of 1.15 million shares, but the shares remain below both the 50-day moving average of $99.01 and the 200-day moving average of $96.18, suggesting room for further upside if momentum builds toward the expected European approval.
Analysts remain broadly optimistic about the company's prospects. The consensus analyst target price stands at $137.60, representing roughly 63% upside from current levels, with 15 analysts rating the stock a buy or strong buy and just one recommending hold, according to market data. The stock has traded in a 52-week range of $45.91 to $122.20.
Rhythm reported trailing 12-month revenue of $189.8 million, up 36.9% year-over-year, though the company remains unprofitable with earnings per share of negative $3.11. The company's strong revenue growth and expanding market opportunity have attracted significant institutional interest, with institutional ownership at 108.9%.
The European expansion would represent an important geographical diversification for IMCIVREE, building on the drug's existing approvals for other rare obesity indications. The therapy targets the root cause of weight gain in rare genetic disorders affecting the melanocortin-4 receptor pathway, offering a precision medicine approach where conventional diet and exercise interventions typically fail.
Looking ahead, investors will be monitoring the European Commission's final decision in the second quarter, as well as uptake metrics in newly approved indications. With the stock trading at approximately 30 times trailing revenue, continued execution on the commercialization front will be critical to sustaining the premium valuation assigned by the market.